Plasmodium falciparum pre-erythrocytic stage vaccine development

Worldwide strategies between 2010 and 2017 aimed at controlling malarial parasites (mainly Plasmodium falciparum) led to a reduction of just 18% regarding disease incidence rates. Many biologically-derived anti-malarial vaccine candidates have been developed to date; this has involved using many exp...

Full description

Autores:

Tipo de recurso:

Fecha de publicación:

2020

Institución:

Universidad del Rosario

Repositorio:

Repositorio EdocUR - U. Rosario

Idioma:

eng

OAI Identifier:

oai:repository.urosario.edu.co:10336/22549

Acceso en línea:

https://doi.org/10.1186/s12936-020-3141-z
https://repository.urosario.edu.co/handle/10336/22549

Palabra clave:

Atovaquone plus proguanil
Azithromycin
Chimpanzee adenovirus 63 modified vaccinia virus
Chloroquine
Csvac vaccine
Genetically attenuated sporozoite vaccine
Live vaccine
Malaria vaccine
Mefloquine
Mva metrap vaccine
Pyrimethamine
R21 vaccine
Radiation attenuated sporozoite
Recombinant protein vaccine
Recombinant viral vector vaccine
Unclassified drug
Virus vector
Drug safety
Hepatitis
Human
Malaria
Malaria control
Nonhuman
Plasmodium (life cycle stage)
Plasmodium falciparum
Review
Sporozoite
Vaccination coverage
Vaccine immunogenicity
Vaccine production
Clinical trial
Immune response
Malaria
Sporozoite
Vaccine
Vaccine efficacy
s vaccine
Rts

Rights

License

Abierto (Texto Completo)